Primmune Therapeutics
Develops oral small-molecule TLR7 agonists for systemic cancer immunotherapy.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredSep 1, 2017 (9 years old)
Funding rounds
- Series B+ · amount undisclosedSource: fundraisingfox.com
- Website created
Founders and team
JA
James Appleman SVP, R&D and CSO Cofounder, Directorsource: primmunerx.comPR
Paulo Rangel Chief Business Officer and Cofoundersource: primmunerx.com
Companies like Primmune Therapeutics
HHephaistos-Pharma$4.89M Seed · May 2024AAlzheon$100M Series B+ · Apr 2022
RRgenta TherapeuticsSeries B+ · Nov 2026
MMwyngil TherapeuticsSeed · Jun 2026
SStorm Therapeutics$56M Series B+ · Apr 2026
CCellCentric$220M Series B+ · May 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/primmune-therapeutics (get a free API key).